City Therapeutics (CTY) 10% Owner LLC Buys $3.1M of Stock
Key Points
- ARCH Venture Partners XII, LLC acquired 170,000 shares of City Therapeutics, Inc. (CTY) at $18.00 per share on October 19, 2026, totaling $3.06 million.
- Following the Form 4 filing with the SEC, the 10% owner holds 13,692,507 shares, raising its stake by about 1.26%.
- City Therapeutics operates out of Cambridge, Massachusetts, developing RNA interference treatments for various medical conditions.
Get City Therapeutics text alerts
We text you when insiders, Congress, analysts or big funds move on $CTY.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated City Therapeutics, Inc. alert may contain errors. Disclosures
ARCH Venture Partners XII, LLC purchased 170,000 shares of City Therapeutics, Inc. (CTY) on October 19, 2026. The details of this purchase appear in a Form 4 filing with the SEC.
CTY
City Therapeutics, Inc.
ARCH Venture Partners XII, LLC vs. the S&P 500
Hypothetical returns from ARCH Venture Partners XII, LLC's disclosed trades, not real profit or advice. How we model this.
Inside ARCH Venture Partners XII's City Therapeutics Trade
The 10% owner picked up 170,000 shares at a price of $18.00 apiece, bringing the total transaction value to $3.06 million. After this purchase, the entity holds 13,692,507 shares of the biotech firm. This trade increased its holdings by roughly 1.26%.
City Therapeutics, Inc. Stock Down 4.2%
The stock recently traded around $21.46 as of October 19, 2026.
Recent Earnings
City Therapeutics reported trailing twelve month revenue of $14.3 million alongside year-over-year revenue growth of 14.0%.
About City Therapeutics
Based in Cambridge, Massachusetts, City Therapeutics focuses on creating RNA interference medicines using engineered small interfering RNAs to target various conditions, including retinal diseases.
Bottom Line
Investors can track future SEC filings to monitor how major stakeholders adjust their positions in City Therapeutics.
Related Filing Alerts
Source: ARCH Venture Partners XII, LLC's Form 4 filing on $CTY (Oct 19, 2026). Written by software, not financial advice. How we make alerts